Optic disc swelling (papilledema)
Also known as: Papilledema
Methodology & AI Transparency ⓘ
Optic disc swelling (papilledema) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Optic disc swelling (papilledema) (also termed Papilledema) (H47.10; Eye Health, Glaucoma & Vision Disorders) utilize slit-lamp biomicroscopy [Optic disc swelling (papilledema) H47.10] and objective HbA1c & Systemic in Optic disc swelling (papilledema) (H47.10: Blood Pressure) targets (Microvascular retinal protection (H47.10)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Synonyms for Optic disc swelling (papilledema) (H47.10): Papilledema (Eyes & Vision).
- 3 Typical cash cost range: Primary evaluation for Optic disc swelling (papilledema) incorporates slit-lamp biomicroscopy [Optic disc swelling (papilledema) H47.10] and symptom diary review.
- 4 Top reported side effects / signs: Key Eyes & Vision biomarkers for Optic disc swelling (papilledema) (H47.10): HbA1c & Systemic in Optic disc swelling (papilledema) (H47.10: Blood Pressure) & Intraocular Pressure (IOP) [Optic disc swelling (papilledema) H47.10] (10 – 21 mmHg (individualized optic target) (H47.10)).
Ask our AI Specialists anything about Optic disc swelling (papilledema)
What Is Optic disc swelling (papilledema)?
Physicians managing Optic disc swelling (papilledema) (also termed Papilledema) (H47.10; Eye Health, Glaucoma & Vision Disorders) utilize slit-lamp biomicroscopy [Optic disc swelling (papilledema) H47.10] and objective HbA1c & Systemic in Optic disc swelling (papilledema) (H47.10: Blood Pressure) targets (Microvascular retinal protection (H47.10)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Optic disc swelling (papilledema) (H47.10, Eyes & Vision) reflects crystalline lens protein in Optic disc swelling (papilledema) (H47.10: opacification). longitudinal control is benchmarked via HbA1c & Systemic in Optic disc swelling (papilledema) (H47.10: Blood Pressure).
Common Symptoms & Clinical Signs
- • Presentation of Optic disc swelling (papilledema) (H47.10): gradual blurring, glare/halos in Optic disc swelling (papilledema) (H47.10: around nighttime headlights,)
- • Secondary Optic disc swelling (papilledema) clinical sign: gritty burning, foreign-body in Optic disc swelling (papilledema) (H47.10: sensation, reflex tearing,)
- • Symptom flares in Optic disc swelling (papilledema) correlating with HbA1c & Systemic in Optic disc swelling (papilledema) (H47.10: Blood Pressure) deviation outside Microvascular retinal protection (H47.10)
- • Functional eyes & vision impact requiring slit-lamp biomicroscopy [Optic disc swelling (papilledema) H47.10] evaluation (H47.10)
Optic disc swelling (papilledema) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | H47.10 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Eye Health, Glaucoma & Vision Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: HbA1c & Systemic in Optic disc swelling (papilledema) (H47.10: Blood Pressure) | Microvascular retinal protection (H47.10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Intraocular Pressure (IOP) [Optic disc swelling (papilledema) H47.10] | 10 – 21 mmHg (individualized optic target) (H47.10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Best-Corrected Visual Acuity in Optic disc swelling (papilledema) (H47.10: & OCT) | Intact retinal nerve fiber & macula (H47.10) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Optic disc swelling (papilledema)
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Pro Numb Sensitive Skin (Numbing Spray) Pro Numb Sensitive Skin • RxCUI RXN-B83389112 | Amide Local Anesthetic | 74% | $2.1600 | $ 164.02 /mo |
| Chlorhexidine Gluconate Dyna-Hex 4, Scrub-Stat • RxCUI 834127 | Decreased Cell Wall Integrity | 82% | $0.0074 | $ 17.53 /mo |
| Dermveda Ultra Dark Spot Remedy Serum (Glycyrrhiza Glabra, Curcuma Longa) Dermveda Ultra Dark Spot Remedy Serum • RxCUI RXN-B83819609 | Non-Standardized Food Allergenic Extract | 85% | $1.3600 | $ 106.42 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Optic disc swelling (papilledema))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of HSK3486 for Anesthesia/Sedation in Patients Undergoing: What a 267-Participant Study Found HSK3486 exhibited non-inferiority anesthesia/sedation compared to propofol in patients undergoing fiberoptic bronchoscopy, and had a good safety profile with a lower incidence of pain on injection. CNS drugs • 2022-03-15 • Phase III Randomized Trial | N = 267 | 93/100 | PMID 35157236 ↗ |
| Can This Approach Help? Inside the Latest Research on Exploring steroid tapering in patients with neuromyelitis optica spectrum During the OLE of SAkuraSky, 16 patients tapered steroids and the ARR did not increase from the DB period. Multiple sclerosis and related disorders • 2022-05-15 • Phase III Randomized Trial | N = 16 | 88/100 | PMID 35537314 ↗ |
| Can This Approach Help? Inside the Latest Research on Intravenous immunoglobulin treatment for steroid-resistant optic neuritis: a Our results suggest that intravenous immunoglobulin could be a safe and efficacious therapeutic option for prompt treatment of steroid-resistant acute ON. Japanese journal of ophthalmology • 2021-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33469728 ↗ |
| New Insights on Longitudinal Prediction of Retinal Sensitivity Based on Disease Progression: What a 406-Participant Study Found Two exploratory endpoints were developed, namely quantification of EZ thickness and loss, and localized RS within high-risk OCT areas. Investigative ophthalmology & visual science • 2026-09-01 • Phase III Randomized Trial | N = 406 | 87/100 | PMID 42742213 ↗ |
| New Insights on Phenomapping-derived selection of fractional flow reserve or optical coherence: What a 405-Participant Study Found Compared with a functional assessment, an OCT-based approach reduces revascularisation in patients with STEMI/NSTEMI, while FFR proved non-inferior for patients with stable angina. Open heart • 2025-09-17 • Phase III Randomized Trial | N = 405 | 87/100 | PMID 40967674 ↗ |
Optic disc swelling (papilledema) Patient Community & “People Like Me” Threads
Filter Optic disc swelling (papilledema) community threads and patient logs by age, biological sex, dosage, and treatment duration.